Replies to post #81 on Sangamo Biosciences Inc (SGMO)

[surf1944]

7:17AM On The Wires (WIRES) :

Sangamo BioSciences (SGMO) announced the publication of a preclinical study demonstrating permanent functional correction of the gene that causes hemophilia B by the systemic delivery of zinc finger nucleases. The study, published in Nature, represents a significant advance in the development and systemic delivery of ZFP Therapeutics and proof of concept for ZFN-based gene-editing for the treatment of hemophilia and other monogenic diseases.